Form 4: NewAmsterdam Pharma Co N.V. Executive Acquires Options

Juliette Berangere Audet, Chief Strategy and Business Officer of NewAmsterdam Pharma Co N.V., acquired options to purchase 30,000 ordinary shares.

Summary

• Juliette Berangere Audet, Chief Strategy and Business Officer of NewAmsterdam Pharma Co N.V., filed a Form 4.
• On May 1, 2025, Audet acquired options to purchase 30,000 ordinary shares at an exercise price of $20.03.
• The options vest over four years, with 25% vesting on May 1, 2026, and the remainder vesting monthly thereafter, contingent upon continued service.
• Following the transaction, Audet directly owns options for 30,000 ordinary shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of executive compensation. The vesting schedule suggests a commitment from the executive.

Positives

• The acquisition of options by a key executive could be seen as a positive sign of their confidence in the company's future.

Future Outlook

The vesting schedule indicates a four-year commitment from the executive, suggesting a long-term focus.

Industry Context

Form 4 filings are routine disclosures of insider transactions, providing transparency to the market.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, reflecting confidence from a key executive.

Key Dates

Keywords

Form 4, NewAmsterdam Pharma, Executive Compensation, Stock Options, Insider Trading, NAMS, Audet